Table 5. Open in new tab Association of...

	Resistance Mutations Present in 23S rRNA
Persistent symptoms at Day 15^a
Yes	26 (35.1)	(24.4–47.1)	2 (8.7)	(1.1–28)
No	43 (58.1)	(46.1–69.5)	21 (91.3)	(72–98.9)
Incongruent: symptoms not reported at enrollment but reported as persistent at Day 15	3 (4.1)	(.8–11.4)	0 (0)	(0–14.8)
Incongruent: symptoms reported at enrollment but denied ever having at Day 15	2 (2.7)	(.3–9.4)	0 (0)	(0–14.8)
Returned at least once within 45 days of enrollment^b
Yes	23 (27.1)	(18–37.8)	2 (7.1)	(.9–23.5)
No	62 (72.9)	(62.2–82)	26 (92.9)	(76.5–99.1)

	Resistance Mutations Present in 23S rRNA
Persistent symptoms at Day 15^a
Yes	26 (35.1)	(24.4–47.1)	2 (8.7)	(1.1–28)
No	43 (58.1)	(46.1–69.5)	21 (91.3)	(72–98.9)
Incongruent: symptoms not reported at enrollment but reported as persistent at Day 15	3 (4.1)	(.8–11.4)	0 (0)	(0–14.8)
Incongruent: symptoms reported at enrollment but denied ever having at Day 15	2 (2.7)	(.3–9.4)	0 (0)	(0–14.8)
Returned at least once within 45 days of enrollment^b
Yes	23 (27.1)	(18–37.8)	2 (7.1)	(.9–23.5)
No	62 (72.9)	(62.2–82)	26 (92.9)	(76.5–99.1)

Table 5.

Association of Self-reported Persistent Urethritis and Return Visits with Macrolide Resistance Markers

	Resistance Mutations Present in 23S rRNA
	Yes, n = 85		No, n = 30
	n (%)	(95% CI)	n (%)	(95% CI)
Persistent symptoms at Day 15^a
Yes	26 (35.1)	(24.4–47.1)	2 (8.7)	(1.1–28)
No	43 (58.1)	(46.1–69.5)	21 (91.3)	(72–98.9)
Incongruent: symptoms not reported at enrollment but reported as persistent at Day 15	3 (4.1)	(.8–11.4)	0 (0)	(0–14.8)
Incongruent: symptoms reported at enrollment but denied ever having at Day 15	2 (2.7)	(.3–9.4)	0 (0)	(0–14.8)
Returned at least once within 45 days of enrollment^b
Yes	23 (27.1)	(18–37.8)	2 (7.1)	(.9–23.5)
No	62 (72.9)	(62.2–82)	26 (92.9)	(76.5–99.1)

	Resistance Mutations Present in 23S rRNA
	Yes, n = 85		No, n = 30
	n (%)	(95% CI)	n (%)	(95% CI)
Persistent symptoms at Day 15^a
Yes	26 (35.1)	(24.4–47.1)	2 (8.7)	(1.1–28)
No	43 (58.1)	(46.1–69.5)	21 (91.3)	(72–98.9)
Incongruent: symptoms not reported at enrollment but reported as persistent at Day 15	3 (4.1)	(.8–11.4)	0 (0)	(0–14.8)
Incongruent: symptoms reported at enrollment but denied ever having at Day 15	2 (2.7)	(.3–9.4)	0 (0)	(0–14.8)
Returned at least once within 45 days of enrollment^b
Yes	23 (27.1)	(18–37.8)	2 (7.1)	(.9–23.5)
No	62 (72.9)	(62.2–82)	26 (92.9)	(76.5–99.1)

Data are among men in the primary evaluable population who have analyzable Day 15 data, are positive for Mycoplasma genitalium only, and were treated with azithromycin, stratified by the presence or absence of macrolide resistance mutations (23S rRNA), July 2017–June 2018.

Abbreviations: CI, confidence interval; rRNA, ribosomal ribonucleic acid.

^aAmong 97 (74 with 23S mutations present and 23 without) participants with analyzable Day 15 data.

^bAmong 113 (85 with 23S mutations present and 28 without) participants with analyzable return data.

This Feature Is Available To Subscribers Only